Get started
Author

Michael H. Cullen

Observed names: Michael Cullen, Michael H Cullen
Observed institutions: Brighton and Sussex Medical School, Leeds General Infirmary, St Bartholomew's Hospital, University Hospitals Birmingham NHS Foundation Trust, Charles University, Barts Health NHS Trust, Queen Elizabeth Hospital Birmingham, Heart of England NHS Foundation Trust, Royal Bournemouth Hospital, Yorkshire Cancer Research, Cancer Research UK, Southampton General Hospital, Weston Park Cancer Centre, Fakultní nemocnice Bulovka, University of Manchester, Heartlands Hospital, The Christie Hospital, Cancer Research UK Clinical Trials Unit, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Southampton, University College London, Imperial College London, University of Birmingham, Medical Research Council
OpenAlex ID: A5111916766
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
1999 · M. H. Cullen, L. J. Billingham, et al. · Journal of Clinical Oncology · 445
Management of febrile neutropenia: ESMO Clinical Practice Guidelines
2010 · J. de Naurois, I. Novitzky-Basso, et al. · Annals of Oncology · 435
PDF
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
2005 · Michael Cullen, Neil Steven, et al. · New England Journal of Medicine · 422
PDF
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.
1992 · G Read, S P Stenning, et al. · Journal of Clinical Oncology · 415
Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial
1999 · S.D. Fosså, A. Horwich, et al. · Journal of Clinical Oncology · 384
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
1997 · A Horwich, D T Sleijfer, et al. · Journal of Clinical Oncology · 333
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.
1996 · M H Cullen, S P Stenning, et al. · Journal of Clinical Oncology · 310
Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
2008 · Lucio Crinò, Federico Cappuzzo, et al. · Journal of Clinical Oncology · 217
Antibiotic prophylaxis in neutropenic patients
2006 · Leonard Leibovici, Mical Paul, et al. · Cancer · 203
PDF
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
1998 · S B Kaye, G M Mead, et al. · Journal of Clinical Oncology · 186
Histological transformation of non-hodgkin's lymphoma.A prospective study
1979 · M. H. Cullen, T. A. Lister, et al. · Cancer · 165
PDF
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.
1978 · T A Lister, M H Cullen, et al. · BMJ · 155
PDF
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
1999 · S D Fosså, S P Stenning, et al. · British Journal of Cancer · 147
PDF
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
1998 · S D Fosså, S B Kaye, et al. · Journal of Clinical Oncology · 145
Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
2005 · Peter W.M. Johnson, John A. Radford, et al. · Journal of Clinical Oncology · 135
PDF
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
2005 · on behalf of the MRC Testicular Tumour Working Party, G M Mead, et al. · British Journal of Cancer · 130
PDF
Prevention of Effects of Alcohol Intoxication by Naloxone
1979 · W.J. Jeffcoate, M.H. Cullen, et al. · The Lancet · 129
Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare
1988 · MH Cullen, R Joshi, et al. · British Journal of Cancer · 122
PDF
P-glycoprotein possesses A 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site
1992 · David R. Ferry, Michael A. Russell, et al. · Biochemical and Biophysical Research Communications · 120
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
2017 · Michael J. Seckl, Christian H. Ottensmeier, et al. · Journal of Clinical Oncology · 116
A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
2000 · A Horwich, R T D Oliver, et al. · British Journal of Cancer · 108
PDF
Long-term toxicity of chemotherapy for testicular cancer – the cost of cure
1990 · NSA Stuart, CM Woodroffe, et al. · British Journal of Cancer · 96
PDF
The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer
2001 · L.J. Billingham, M.H. Cullen · Annals of Oncology · 92
PDF
Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role
1997 · G.M. Duchesne, S.P. Stenning, et al. · European Journal of Cancer · 90
Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)
2010 · Peter W.M. Johnson, Matthew R. Sydes, et al. · Journal of Clinical Oncology · 85
PDF
Works count: 57
Citation count: 2,080
H-index: 20
I10-index: 33
Year
Topic
Type